Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
REPR's Cash to Debt is ranked higher than
92% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. REPR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
REPR' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.43 Max: No Debt
Current: No Debt
Equity to Asset 0.83
REPR's Equity to Asset is ranked higher than
82% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. REPR: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
REPR' s Equity to Asset Range Over the Past 10 Years
Min: -0.85  Med: 0.39 Max: 0.86
Current: 0.83
-0.85
0.86
Interest Coverage 68.46
REPR's Interest Coverage is ranked higher than
63% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.08 vs. REPR: 68.46 )
Ranked among companies with meaningful Interest Coverage only.
REPR' s Interest Coverage Range Over the Past 10 Years
Min: 0.97  Med: 37.93 Max: 1147
Current: 68.46
0.97
1147
F-Score: 8
Z-Score: 10.53
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 7.06
REPR's Operating margin (%) is ranked higher than
57% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. REPR: 7.06 )
Ranked among companies with meaningful Operating margin (%) only.
REPR' s Operating margin (%) Range Over the Past 10 Years
Min: -1.27  Med: 12.64 Max: 24.28
Current: 7.06
-1.27
24.28
Net-margin (%) 4.88
REPR's Net-margin (%) is ranked higher than
57% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. REPR: 4.88 )
Ranked among companies with meaningful Net-margin (%) only.
REPR' s Net-margin (%) Range Over the Past 10 Years
Min: -14.7  Med: 8.72 Max: 29.98
Current: 4.88
-14.7
29.98
ROE (%) 9.15
REPR's ROE (%) is ranked higher than
63% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. REPR: 9.15 )
Ranked among companies with meaningful ROE (%) only.
REPR' s ROE (%) Range Over the Past 10 Years
Min: 11.69  Med: 22.71 Max: 639.38
Current: 9.15
11.69
639.38
ROA (%) 7.68
REPR's ROA (%) is ranked higher than
75% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.92 vs. REPR: 7.68 )
Ranked among companies with meaningful ROA (%) only.
REPR' s ROA (%) Range Over the Past 10 Years
Min: -24.82  Med: 12.94 Max: 57.04
Current: 7.68
-24.82
57.04
ROC (Joel Greenblatt) (%) 26.74
REPR's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. REPR: 26.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
REPR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -55.86  Med: 44.03 Max: 95.45
Current: 26.74
-55.86
95.45
Revenue Growth (3Y)(%) 14.40
REPR's Revenue Growth (3Y)(%) is ranked higher than
85% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. REPR: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
REPR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 14.45 Max: 26.2
Current: 14.4
-9.9
26.2
EBITDA Growth (3Y)(%) 2.80
REPR's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. REPR: 2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
REPR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.1  Med: 2.80 Max: 91.3
Current: 2.8
-34.1
91.3
» REPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with REPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:AKER, OTCPK:UEEC, NAS:DXTR, OTCBB:NEPH, OTCPK:BMRA, OTCPK:IGAP, NAS:PDEX, OTCPK:ERGVF, NAS:SKLN, NAS:NURO, NAS:BLFS, NAS:SSKN, OTCPK:REMI, OTCPK:PEYE, NAS:STXS, OTCPK:ECIA, OTCPK:RXSF, OTCPK:VPTDF, OTCPK:RSCF, AMEX:DXR » details
Repro-Med Systems Inc designs, manufactures and markets proprietary medical devices for ambulatory infusion market and emergency medical applications.

Repro-Med Systems Inc was incorporated in the State of New York in March of 1980. The Company designs, manufactures and markets proprietary medical devices mainly for emergency medical applications and ambulatory infusion therapy. These products are regulated by the FDA. Its development and marketing focus are concentrated on the RES-Q-VAC(R) and the FREEDOM60(R) products. The FREEDOM60 uses 'engine' to create a constant pressure drive system. FREEDOM60(R) uses rate-controlled tubing with standard slide clamp and luer-lock connector on the patient end. Proprietary technology Employed in the FREEDOM60 uses constant pressure to administer drugs. FREEDOM60 avoids an important problem faced by electronic pumps currently on the market which Employ constant flow mechanisms that result in potentially dangerous, high pressures placed on indwelling catheters or under the skin. The Freedom60 Syringe Infusion Pump is designed for ambulatory medication infusions. The Company also designed and manufactured the Freedom60-FM, an enhanced version of the Freedom60 which contains an electronic flow monitor system that provides occlusion and end of infusion alarm. The Freedom60 use for Primary Immune Deficiency by injecting immune globulin under the skin as a subcutaneous administration continued to increase usage during the past year. This method has provided patients with improved quality of life with much fewer unpleasant side effects over the traditional intravenous route. The RES-Q-VAC(R) Emergency Airway Suction System is a lightweight, portable, hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC(R) pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. The Company has introduced new, updated features including the FSP filter, new pediatric connectors, new graduated canister, new adult catheters, and new convenient carry pouch. It is also available with a flexible, portable LED white light source, which is attached to the top of the canister system and provides illumination for the medical professional during nighttime or low light conditions. The Company offers its products directly to large national accounts and emergency medical device distributors, as well as to regional distributors in the hospital respiratory care market.

Ratios

vs
industry
vs
history
P/E(ttm) 43.00
REPR's P/E(ttm) is ranked lower than
74% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. REPR: 43.00 )
Ranked among companies with meaningful P/E(ttm) only.
REPR' s P/E(ttm) Range Over the Past 10 Years
Min: 4.4  Med: 14.50 Max: 90
Current: 43
4.4
90
PE(NRI) 43.00
REPR's PE(NRI) is ranked lower than
75% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. REPR: 43.00 )
Ranked among companies with meaningful PE(NRI) only.
REPR' s PE(NRI) Range Over the Past 10 Years
Min: 2.75  Med: 12.84 Max: 43
Current: 43
2.75
43
Price/Owner Earnings (ttm) 14.34
REPR's Price/Owner Earnings (ttm) is ranked higher than
79% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.98 vs. REPR: 14.34 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
REPR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.33  Med: 17.73 Max: 260
Current: 14.34
3.33
260
P/B 2.36
REPR's P/B is ranked higher than
58% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. REPR: 2.36 )
Ranked among companies with meaningful P/B only.
REPR' s P/B Range Over the Past 10 Years
Min: 1.09  Med: 2.42 Max: 58
Current: 2.36
1.09
58
P/S 1.30
REPR's P/S is ranked higher than
73% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. REPR: 1.30 )
Ranked among companies with meaningful P/S only.
REPR' s P/S Range Over the Past 10 Years
Min: 0.62  Med: 1.37 Max: 3.61
Current: 1.3
0.62
3.61
PFCF 11.02
REPR's PFCF is ranked higher than
88% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.29 vs. REPR: 11.02 )
Ranked among companies with meaningful PFCF only.
REPR' s PFCF Range Over the Past 10 Years
Min: 4.07  Med: 22.00 Max: 450
Current: 11.02
4.07
450
POCF 10.01
REPR's POCF is ranked higher than
78% of the 103 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.88 vs. REPR: 10.01 )
Ranked among companies with meaningful POCF only.
REPR' s POCF Range Over the Past 10 Years
Min: 3.79  Med: 11.79 Max: 200
Current: 10.01
3.79
200
EV-to-EBIT 14.12
REPR's EV-to-EBIT is ranked higher than
68% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.84 vs. REPR: 14.12 )
Ranked among companies with meaningful EV-to-EBIT only.
REPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -104.1  Med: 6.50 Max: 30.5
Current: 14.12
-104.1
30.5
EV-to-EBITDA 10.73
REPR's EV-to-EBITDA is ranked higher than
71% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.39 vs. REPR: 10.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
REPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1110.5  Med: 5.80 Max: 22.6
Current: 10.73
-1110.5
22.6
Shiller P/E 24.17
REPR's Shiller P/E is ranked higher than
77% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.46 vs. REPR: 24.17 )
Ranked among companies with meaningful Shiller P/E only.
REPR' s Shiller P/E Range Over the Past 10 Years
Min: 15  Med: 23.50 Max: 45
Current: 24.17
15
45
Current Ratio 5.66
REPR's Current Ratio is ranked higher than
84% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. REPR: 5.66 )
Ranked among companies with meaningful Current Ratio only.
REPR' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.70 Max: 9.6
Current: 5.66
0.71
9.6
Quick Ratio 4.76
REPR's Quick Ratio is ranked higher than
86% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. REPR: 4.76 )
Ranked among companies with meaningful Quick Ratio only.
REPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.97 Max: 7.47
Current: 4.76
0.19
7.47
Days Inventory 97.63
REPR's Days Inventory is ranked higher than
68% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. REPR: 97.63 )
Ranked among companies with meaningful Days Inventory only.
REPR' s Days Inventory Range Over the Past 10 Years
Min: 81.94  Med: 149.39 Max: 230.05
Current: 97.63
81.94
230.05
Days Sales Outstanding 39.20
REPR's Days Sales Outstanding is ranked higher than
82% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. REPR: 39.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
REPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.23  Med: 52.16 Max: 73.22
Current: 39.2
40.23
73.22
Days Payable 48.40
REPR's Days Payable is ranked lower than
53% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.12 vs. REPR: 48.40 )
Ranked among companies with meaningful Days Payable only.
REPR' s Days Payable Range Over the Past 10 Years
Min: 14.24  Med: 29.52 Max: 243.52
Current: 48.4
14.24
243.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.17
REPR's Price/Net Cash is ranked higher than
63% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.33 vs. REPR: 7.17 )
Ranked among companies with meaningful Price/Net Cash only.
REPR' s Price/Net Cash Range Over the Past 10 Years
Min: 5.83  Med: 10.50 Max: 19.5
Current: 7.17
5.83
19.5
Price/Net Current Asset Value 2.87
REPR's Price/Net Current Asset Value is ranked higher than
81% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. REPR: 2.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
REPR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.75  Med: 3.25 Max: 45
Current: 2.87
1.75
45
Price/Tangible Book 2.39
REPR's Price/Tangible Book is ranked higher than
65% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.52 vs. REPR: 2.39 )
Ranked among companies with meaningful Price/Tangible Book only.
REPR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.5  Med: 3.11 Max: 70
Current: 2.39
1.5
70
Price/Projected FCF 1.19
REPR's Price/Projected FCF is ranked higher than
76% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. REPR: 1.19 )
Ranked among companies with meaningful Price/Projected FCF only.
REPR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.31 Max: 19
Current: 1.19
0.75
19
Price/Median PS Value 0.96
REPR's Price/Median PS Value is ranked higher than
63% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. REPR: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
REPR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 1.00 Max: 2.08
Current: 0.96
0.3
2.08
Price/Graham Number 1.79
REPR's Price/Graham Number is ranked higher than
63% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. REPR: 1.79 )
Ranked among companies with meaningful Price/Graham Number only.
REPR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.91  Med: 1.31 Max: 5.4
Current: 1.79
0.91
5.4
Earnings Yield (Greenblatt) (%) 7.11
REPR's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. REPR: 7.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
REPR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.3  Med: 12.90 Max: 31.7
Current: 7.11
3.3
31.7
Forward Rate of Return (Yacktman) (%) 0.18
REPR's Forward Rate of Return (Yacktman) (%) is ranked lower than
71% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.73 vs. REPR: 0.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
REPR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.9  Med: 4.30 Max: 32
Current: 0.18
-2.9
32

More Statistics

Revenue (TTM) (Mil) $12.61
EPS (TTM) $ 0.01
Beta-0.58
Short Percentage of Float0.00%
52-Week Range $0.25 - 0.59
Shares Outstanding (Mil)37.96
» More Articles for REPR

Headlines

Articles On GuruFocus.com

More From Other Websites
Repro-Med Systems, Inc. :REPR-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016 Jul 22 2016
REPRO MED SYSTEMS INC Financials Jul 06 2016
REPRO MED SYSTEMS INC Files SEC form 10-Q, Quarterly Report Jun 30 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jun 27 2016
RMS Medical Products Posts First Quarter 2017 Results Jun 27 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Other Events Jun 17 2016
Repro-Med Systems, Inc. :REPR-US: Earnings Analysis: Q4, 2016 By the Numbers May 19 2016
Repro Med Systems, Inc. Posts Fourth Quarter and Fiscal Year 2016 Results and Announces New Member... May 18 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... May 18 2016
REPRO MED SYSTEMS INC Files SEC form 10-K, Annual Report May 13 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Other Events Apr 29 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 31 2016
Repro Med Systems, Inc. Gives Business Update Including Preliminary Revenue Results for Q4 2016 Mar 31 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Other Events Mar 18 2016
Markets: Investors Looking Toward Renewed Momentum - Research on SpectraSCIENCE, Blue Sphere,... Mar 11 2016
Repro Med Systems, Inc. Responds to FDA Warning Letter Mar 09 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 29 2016
Repro-Med Systems, Inc. Earnings Analysis: Q3, 2016 By the Numbers Jan 20 2016
REPRO MED SYSTEMS INC Files SEC form 10-Q, Quarterly Report Jan 08 2016
REPRO MED SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Dec 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)